A b s t r a c t Advanced D-dimer (Dade Behring, Marburg, Germany) is a latex-enhanced turbidimetric test for the quantitative determination of D-dimers. To evaluate this assay, examine test performance on 2 instruments (BCS 86%, 34%, 96%, and 15%, respectively. 
D-dimers are cross-linked degradation products of fibrin, and their presence in human plasma is an indicator of fibrinolytic activity. 1 Acute thromboembolic disease, such as pulmonary embolism and deep venous thrombosis, is associated with increased fibrinolysis and increased levels of plasma D-dimers. Variables shown to affect D-dimer levels include age of the patient and clot factors such as location, size, and age of the clot. 2 Because there are many causes of increased fibrinolysis, elevated levels of D-dimer are not specific for acute thromboembolism. 3 In addition, a protein specific for thromboembolic disease has yet to be identified. For these reasons, the importance of laboratory testing of patients with suspected acute thromboembolic disease has mainly been exclusionary on the basis of D-dimer levels that are not elevated. Furthermore, D-dimer testing when used in conjunction with clinical pretest probability has shown efficacy in the evaluation of patients for deep venous thrombosis and pulmonary embolism. [4] [5] [6] Many D-dimer tests are available that use various methods. Laboratory testing for D-dimers may be qualitative, semiquantitative, or quantitative. Qualitative D-dimer tests yield a positive or negative result depending on whether the level of D-dimer in the specimen exceeds the minimum detection level. Qualitative methods include whole blood agglutination (SimpliRed, Agen Biomedical, Brisbane, Australia) and latex agglutination (Minutex Ddimer, Biopool, Umeå, Sweden). 
Materials and Methods

Specimens
Between April 2001 and September 2002, 1,060 whole blood specimens were obtained from inpatients and patients examined in the emergency department, St Vincent Hospital, Indianapolis, IN. A majority of patients were from the emergency department. The patients were being evaluated for possible thromboembolic disease (pulmonary embolus or deep venous thrombosis). Each specimen was drawn into a 4. were confirmed by repeated assay on the same sample. The remaining specimen was spun for 15 minutes at 2,500 rpm, and the platelet-poor plasma was removed. The cellular component was discarded. The platelet-poor specimen was frozen at -70°C for possible Advanced D-dimer testing. Based on the clinical assessment for acute thromboembolism and the SimpliRed result, the attending physician decided whether to pursue additional confirmatory studies. Retrospectively, the medical chart for each patient was reviewed for eligibility in the Advanced D-dimer assay study. Institutional review board approval had been obtained. For cases to be eligible for study inclusion, a confirmatory radiologic study must have been done and exclusionary medical conditions must not be present. Confirmatory studies for pulmonary embolism included spiral computed tomography, ventilation-perfusion scan, or pulmonary angiogram. Of the patients with a confirmatory ventilationperfusion scan, only those with a high probability were considered positive for pulmonary embolus. The confirmatory study for deep venous thrombosis was a venous Doppler study. The medical conditions that excluded cases from the study were those that might be associated with increased Ddimer levels and included multiple system trauma, myocardial infarction, stroke, acute infection, disseminated intravascular coagulation, active collagen vascular disease, cancer, surgery, and pregnancy. By using these guidelines, 117 (11.03%) of 1,060 cases were eligible for the study; 49.81% (528/1,060) were excluded owing to lack of confirmatory studies and 39.15% (415/1,060) to medical conditions. The Advanced D-dimer assay was performed on the BCS Analyzer and Sysmex CA-1500 instruments. Linearity studies were performed before testing through ranges of 0.43 to 51.46 mg/L on the BCS Analyzer and 0.43 to 17.15 mg/L on the Sysmex CA-1500. The intraassay precision ranged from 2% to 3%. A platelet-poor plasma aliquot from each eligible case was run on each instrument. Testing was performed in duplicate, and a mean result was calculated so that each case had 1 result per instrument. The instruments reported the D-dimer results as actual mass units of D-dimer expressed in mg/L and not as the fibrinogen equivalent unit. For comparison, samples from 25 healthy control subjects from a purchased pool normal core set were tested on each instrument.
Results
Clinical Data
Of the 117 patients, 14 had radiologically proven pulmonary embolus, deep venous thrombosis, or both. The results for the Advanced D-dimer and SimpliRed are listed in ❚Table 2❚. The results for the healthy control subjects are listed in ❚Table 3❚. The sensitivity, specificity, positive predictive value, and negative predictive value for a range of values between 0.0 and 3.0 mg/L were calculated for the Advanced D-dimer test on the BCS Analyzer and Sysmex CA-1500 instruments ❚Table 4❚. For comparison, the sensitivity, specificity, positive predictive value, and negative predictive value for the SimpliRed test were 0.86, 0.34, 0.15, and 0.96, respectively.
Discussion
This study demonstrates several important findings. The BCS Analyzer and the Sysmex CA-1500 had substantial test performance differences. At all but one negative predictive value cutoff (NPVC; 2.3 mg/L), the BCS Analyzer had sensitivity and negative predictive value equal to or higher than values for the Sysmex CA-1500. However, the correlation coefficient for Advanced D-dimer tests on the BCS Analyzer and Sysmex CA-1500 was only 82.6%. The reason for the modest correlation is uncertain, but it may indicate that the Advanced D-dimer assay is a different test with different results for each instrument. Given the low correlation, an NPVC was established for each instrument.
It is important to clarify that for D-dimer testing, there is an expected reference range in which the results for healthy subjects would be expected to fall. For the Advanced Ddimer assay on the BCS Analyzer, a reference range is approximately 0.54 to 2.09 mg/L, but this range varies from laboratory to laboratory. The NPVC will fall within the reference range; however, this should not be considered synonymous with the lower or upper limit of the reference range. The present study was intended to determine the NPVC for acute thromboembolic disease for the Advanced D-dimer assay on these 2 instruments and not to determine or validate a D-dimer reference range.
The selected NPVC for the Advanced D-dimer assay should be a value in which the sensitivity and negative predictive value were 100% and the specificity was optimized. It is important to optimize the specificity, because the specificity of a test is related inversely to the number of false-positive results. In general, medical tests with higher false-positive rates have less usefulness and require additional diagnostic testing. Therefore, the lower the specificity for a test, the lower the usefulness of the test and the more testing patients require. Nevertheless, for D-dimer testing, specificity is not as critical as the sensitivity and negative predictive value.
The value of D-dimer tests in the evaluation of patients for possible acute thromboembolic disease is principally in their sensitivity and negative predictive value. Based on and sensitivity, specificity, negative predictive value, and positive predictive value of 100%, 48%, 100%, and 21%, respectively. An NPVC of 1.1 mg/L for the Sysmex CA-1500 resulted in 31.6% negative cases (37/117) and sensitivity, specificity, negative predictive value, and positive predictive value of 100%, 36%, 100%, and 18%, respectively. By comparison, the SimpliRed had 31.6% negative results (37/117) and sensitivity, specificity, negative predictive value, and positive predictive value of 86%, 34%, 96%, and 15%, respectively. The NPVCs in our study are greater than the 0.5 to 1.0 mg/L negative cutoff range that has been reported for many of the other quantitative D-dimer tests ( Table 1 ). The disparity between the published values for other quantitative D-dimer tests and those for the Advanced D-dimer NPVCs might be the result of any of the following: the published values may represent a lower reference range limit rather than a true NPVC for acute thromboembolic disease; they may indicate a more conservative NPVC so as to optimize sensitivity and negative predictive value; or the disparity may be a reflection of different testing methods or instrumentation.
Regardless, a more conservative NPVC in the range of 0.5 to 0.8 mg/L could be used for the Advanced D-dimer assays with the same 100% sensitivity and 100% negative predictive value as the proposed NPVCs, but it would be at the expense of the specificity. Application of an NPVC of 0.5 mg/L to the Advanced D-dimer assay is problematic given the resultant low specificity (0.03 and 0.19 for the BCS Analyzer and Sysmex CA-1500, respectively), and, therefore, very high numbers of false-positive results will be encountered. Furthermore, this level is near the lower detection limit for this test (0.43 mg/L).
Although the establishment of NPVCs may be labor intensive, laboratories with either instrument should consider establishing internal NPVCs. If an NPVC from this study is used, it should be reported with a comment to reaffirm to clinicians that D-dimer results should always be used in conjunction with the clinical impression.
Another observation of this study is the effect of a patient's age on the D-dimer level. By using data only from cases in the negative acute thromboembolic group, we found no association with the age of the patient and the quantitative D-dimer level (correlation coefficient, -0.06 for the BCS Analyzer and 0.05 for the Sysmex CA-1500). The conclusion that can be drawn is uncertain. It may indicate that the preexisting medical conditions associated with older age that are responsible for the reported increase in D-dimer levels with age and that age by itself is not an independent factor in elevated D-dimer levels. On the other hand, the negative acute thromboembolic group may not be considered equivalent to a healthy outpatient population, and therefore this comparison is not valid.
For the 3 tests studied, the Advanced D-dimer on the BCS Analyzer had the best sensitivity and negative predictive value. If an NPVC had been assigned between 0.5 and 2.0 mg/L, the BCS Analyzer had better sensitivity and negative predictive value than the Sysmex CA-1500 and SimpliRed test. As for the Advanced D-dimer on the Sysmex CA-1500 and the SimpliRed test, the results were comparable to slightly improved with the Sysmex CA-1500. For an NPVC in the range between 0.5 and 1.1 mg/L, the Sysmex CA-1500 had a better sensitivity and a better negative predictive value than the SimpliRed test. However, for negative cutoff values in the 1.2 to 2.0 mg/L range, the results of each of these tests were comparable for sensitivity and negative predictive value.
Beyond the comparable to improved sensitivity and negative predictive value for the Advanced D-dimer assay, there are other important testing considerations. SimpliRed is a manual test that requires some subjective interpretation by the technical staff, and all positive results require repeated confirmation as prescribed by the package insert. The Advanced D-dimer test is an automated test that may be batched and requires no technical interpretation, and repeated testing is not necessary. One disadvantage of the Advanced D-dimer assay is the expense of the instrumentation and testing. This test is more expensive than the SimpliRed, and use in a smaller laboratory may not be feasible. In addition, the SimpliRed test requires a smaller blood specimen (can be performed on a capillary blood specimen from a finger stick), and it can be performed at the bedside. The technician and turnaround times are similar for all 3 assays. Last, and most important, the Advanced Ddimer assay, like other D-dimer tests, is limited by low specificity. The Advanced D-dimer offers specificity comparable to that of the SimpliRed test, but the specificity remains low. D-dimer assays such as the Advanced D-dimer should be used for patients with a low clinical probability for acute thromboembolic disease as further evidence for the absence of thromboembolic disease. The clinical probability should be based on patient history and physical examination. Patients with a low clinical probability for thromboembolic disease and a negative D-dimer assay result likely do not have thromboembolic disease, and diagnostic studies are not necessary. For patients with a low clinical probability of thromboembolic disease and a positive D-dimer result, diagnostic studies may be considered. For patients with moderate to high clinical probability of thromboembolic disease, diagnostic studies will be performed regardless of the D-dimer result, and, therefore, these tests are of little use for this group.
The present study was intended to evaluate the Advanced D-dimer assay on 2 instruments and to establish NPVCs to assist in the exclusion of deep venous thrombosis, pulmonary embolism, or both in patients with no predisposition for increased D-dimer levels. The Advanced D-dimer assay results showed modest correlation between the 2 analyzers. As a result, these tests should be considered different tests with different results for each instrument. Therefore, 2 NPVCs were established. The NPVC values were higher than the negative cutoffs reported for other quantitative D-dimer tests, and each Advanced Ddimer assay using these NPVCs had equal to better sensitivity and negative predictive value than the values for the SimpliRed test. Furthermore, there was no apparent relationship between patient age and D-dimer level in the negative acute thromboembolic group. Although many cases 
